Skip to main content
. 2017 Oct 17;8(55):94681–94691. doi: 10.18632/oncotarget.21866

Table 4. Utility of [99mTc]Tc-Sestamibi (MIBI) for the differentiation between benign and malignant thyroid nodules.

Method Histopathology results Data (%) Total (%)
Benign Malignant
Early images
Score 0 13 (9.4%) 2 (9.1%) 15 (9.3%)
Score 1 46 (33.1%) 5 (22.7%) 51 (31.7%)
Score 2 43 (30.9%) 8 (36.4%) 51 (31.7%)
Score 3 37 (26.6%) 7 (31.8%) 44 (27.3%)
Total (%) 139 (100%) 22 (100%) 161 (100%)
Late images
Score 0 39 (28.1%) 10 (45.5%) 49 (30.4%)
Score 1 41 (29.5%) 3 (13.6%) 30 (18.6%)
Score 2 29 (20.9%) 1 (4.5%) 30 (18.6%)
Score 3 30 (21.6%) 8 (36.4%) 38 (23.6%)
Total (%) 139 (100%) 22 (100%) 161 (100%)
Tracer uptake trend
Decrease (washout) 13 (9.4%) 6 (27.3%) 19 (11.8%)
Increase (retention) 78 (56.1%) 12 (54.5%) 90 (55.9%)
Constant (persistence) 52 (32.3%) 4 (18.2%) 48 (34.5%)
Total (%) 139 (100%) 22 (100%) 161 (100.0%)

The p-value from the early images was not significant, the late images achieved p = 0.044, and the washout/tracer retention method was p = 0.034.